secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-08-25T23:59:59+00:00
Accession:  0001171843-25-005581
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Biosciences appoints EY as auditor and receives additional $1.5M from Hanmi for tuspetinib
--------------------------------------------------------------------------------

- Shareholders voted 96.95% in favor of appointing Ernst & Young LLP as independent registered public accounting firm.
- Received an additional US$1.5M advance from Hanmi Pharmaceutical under the existing US$8.5M loan facility.
- Total advances under the loan facility now US$7.1M to support clinical development of tuspetinib.
- Funds will be used to continue development of tuspetinib-based triple drug frontline therapy for newly diagnosed AML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005581/0001171843-25-005581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325005581/f8k_082525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer